Year None202220212020201920182017 Turning Point Therapeutics to Participate in 42nd Annual Cowen Healthcare Conference Mar 01, 2022 Turning Point Therapeutics Reports Fourth-Quarter and Full Year 2021 Financial Results, Provides Operational Updates Feb 28, 2022 Turning Point Therapeutics to Participate in Upcoming Investor Conferences Feb 02, 2022 Turning Point Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for Combination of Elzovantinib and Aumolertinib in EGFR Mutant Met-Amplified Non-Small Cell Lung Cancer Jan 20, 2022 Turning Point Therapeutics Provides Updates and Anticipated 2022 Clinical and Discovery Pipeline Milestones Jan 18, 2022 Pagination First page « first Previous page ‹ previous Page 1 Current page 2
